Acrivon Therapeutics

ACRV · NASDAQ

$1.80+$0.105 (+6.21%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $1.69

ACRV analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $12.44 (+593.3% upside)

Low: $7.07
Now: $1.80
High: $19.95

Upgrades and downgrades

The latest rating actions, newest first

ACRV analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Piper Sandler	Jan 9, 2026	Maintains	Overweight	$6.00 → $8.00	40%
HC Wainwright & Co.	Nov 25, 2025	Maintains	Buy	$19.00	27%

The case for and against

Updated May 1, 2025

Bull case

Acrivon Therapeutics Inc. has demonstrated a robust advancement in its clinical programs, particularly with ACR-368, which has shown promising efficacy in biomarker-positive endometrial cancer patients and may position the company for an Accelerated Approval in 2026. The encouraging results from preclinical studies indicate that ACR-2316 is more effective in reducing tumor volumes than comparative WEE1 and PKMYT1 inhibitors, suggesting its potential as a best-in-class therapy. Additionally, the firm's strategic focus on matching oncology treatments to genetically characterized patients enhances its competitive edge in the rapidly evolving biopharmaceutical landscape.

Bear case

Acrivon Therapeutics faces significant challenges that contribute to a negative outlook on its stock, including potential clinical holds or approval delays that could hinder future cash flows. The company’s lead program, ACR-368, has demonstrated modest overall response rates in clinical trials, particularly in ovarian and small cell lung cancers, casting doubt on its efficacy. Furthermore, the anticipated financing needs of approximately $225 million through 2037 and concerns surrounding safety signals, competition, and regulatory decisions add additional layers of risk that may adversely impact the company's financial stability and stock performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.